Starling Oncology secures $25M revolving credit line for working capital
What's the deal? Starling Oncology, Inc.Dealroom has a profile for this one. Try Dealroom →'s wholly owned subsidiary, Starling Oncology Management, Limited Liability Company, entered into a revolving credit facility of up to $25 million with Gemino Healthcare FinanceDealroom has a profile for this one. Try Dealroom →, doing business as SLR Healthcare ABLDealroom has a profile for this one. Try Dealroom →. The facility closed on August 21, 2026, and is intended to provide additional financial flexibility for working capital and general corporate purposes.
The mechanics: The facility matures on August 20, 2029, and allows the company to borrow, repay and reborrow throughout the term. As of the closing date, $4.75 million was outstanding. Availability is set by a borrowing-base formula tied to certain accounts receivable, and the obligations are secured by substantially all of the subsidiary's collateral.
The terms: Loans carry interest at Term SOFR plus 3.95%, with Term SOFR floored at 2.00% and reset daily. The agreement includes customary monitoring, unused-line and termination fees.
The signal: This is a post-IPO debt arrangement rather than an equity raise, giving Starling access to capital without dilution. The company is not required or expected to draw the full commitment.
Image credit: Generated with Gemini
Read more: MarketScreener (S&P Capital IQ)
